Plasma-based treatment technology that uses surface-active oxidative species to dramatically reduce bacterial and fungal pathogen loads on stored grains. Validated on wheat, maize, barley, field pea, and psyllium, achieving up to 6-log reduction in pathogen viability. Applicable for improving grain safety, quality, and storage outcomes in agricultural and food industries.
Non-thermal plasma treatment is a chemical-free approach to improving the safety and quality of stored grains. The technology works by generating surface-active oxidative species that inactivate pathogens adhered to grain surfaces without the need for heat or chemical fumigants. This offers a promising alternative or complement to conventional grain treatment methods, particularly for reducing reliance on chemical pesticides and fumigants in post-harvest storage.
The solution has been validated across multiple economically important grain species, including wheat, maize, barley, field pea, and psyllium. It has demonstrated strong efficacy against both endemic and inoculated bacterial and fungal pathogens, achieving reductions in pathogen load of up to six orders of magnitude, including total disinfestation in some cases.
Core technology:
Validated pathogen targets:
Validated grain substrates:
Observed performance:
The technology has reached an advanced stage of laboratory validation. Independent triplicate experiments across five grain types and five major pathogen genera have demonstrated statistically significant pathogen reductions. Planned next-stage validation includes an 8-month partnership to assess impacts on grain nutritional properties, malting performance, and seed surface chemistry, as well as pot studies evaluating germination rate, plant health, and vigour. The research team is also seeking industry advice on translational pathways for commercial deployment.
The University of Adelaide was a comprehensive public research university in South Australia, with a city‑centre campus and specialised sites linking teaching, research and translation. Co‑location within Adelaide BioMed City placed teams beside the Royal Adelaide Hospital and SAHMRI, enabling clinical trials, while AIML at Lot Fourteen linked researchers to an innovation district. At the Waite Research Precinct, co‑located partners and infrastructure such as the Plant Accelerator supported industry‑engaged R&D. Research was backed by national funding, including the Australian Research Council and NHMRC. On January 5, 2026 it merged with the University of South Australia to form Adelaide University; these assets now operate within the new institution with dedicated tech transfer support.